Form 4: Coherus BioSciences Director Sells Entire Stock Holding for Tax Planning

A director at Coherus BioSciences, Mats Wahlstrom, has sold all 99,988 shares of his common stock in the company for tax planning purposes, ceasing all beneficial ownership.

Summary

• Mats Wahlstrom, a Director of Coherus BioSciences, Inc. (CHRS), sold 99,988 shares of common stock.
• The transaction occurred on May 23, 2025.
• The shares were sold at a weighted average price of $0.7389 per share, with individual transactions ranging from $0.7362 to $0.7448.
• Following this sale, Mats Wahlstrom no longer beneficially owns any shares of Coherus BioSciences, Inc., either directly or indirectly through Leonard Capital, LLC.
• The stated reason for the sale was tax planning purposes.

Sentiment

Score: 3

Explanation: The complete divestment of shares by a director, even for tax planning, is a strong negative signal, indicating a lack of confidence or perceived limited upside from an insider's perspective. This typically leads to negative market sentiment.

Negatives

• A director, Mats Wahlstrom, has completely divested his entire beneficial ownership of 99,988 shares in Coherus BioSciences, Inc.
• The sale price of $0.7389 per share is relatively low, which, despite the stated tax planning reason, could be interpreted as a lack of confidence in future price appreciation from the insider's perspective.
• Complete insider divestment can be perceived negatively by the market, potentially signaling concerns about the company's future prospects or valuation.

Risks

• Investor Confidence Erosion: The complete divestment by a director, even if for tax planning, could erode investor confidence and lead to negative market sentiment.
• Perception of Future Performance: Investors might interpret the sale as a signal that the insider does not expect significant future appreciation in the company's stock price.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• "The reported sale transactions were effected for tax planning purposes."
• "The Reporting Person undertakes to provide to Coherus BioSciences, Inc., any security holder of Coherus BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."

Industry Context

This Form 4 filing details an individual insider transaction and does not provide information relevant to broader industry trends or competitive landscape within the biotechnology or pharmaceutical sectors.

Related Party Transactions

• The reporting person's indirect beneficial ownership through Leonard Capital, LLC, where the reporting person and their spouse are members, constitutes a related party relationship. The shares previously held indirectly through this entity have also been divested.

Stakeholder Impact

• Shareholders: May interpret the director's complete divestment as a negative signal, potentially leading to decreased confidence and selling pressure on the stock.
• Employees: No direct impact mentioned, but a significant insider sale could subtly affect morale if perceived as a lack of confidence.

Key Dates

Recommendation

Keywords

Coherus BioSciences, CHRS, Mats Wahlstrom, Insider Trading, Form 4, Stock Sale, Director Sale, Beneficial Ownership, Biotechnology, Pharmaceuticals